Serum Concentrations of Vascular Endothelial Growth Factor in Infants Treated With Ranibizumab for Retinopathy of Prematurity
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 25 Apr 2018 Planned End Date changed from 1 Dec 2018 to 30 Jun 2018.
- 25 Apr 2018 Planned primary completion date changed from 1 Jun 2018 to 31 May 2018.
- 25 Apr 2018 Status changed from not yet recruiting to recruiting.